Curve Perspectives article – Rab Prinjha Rab Prinjha joined Curve Therapeutics in 2024 as Chief R&D Officer, after 25 years at GSK. In this Curve Perspectives article to mark British Science Week, Rab explains why he joined Curve, how Southampton is shaping up as a biotech hub, and the importance of collaboration in the UK […]
Curve Perspectives article – Ali Tavassoli With its powerful Microcycle platform technology, Curve Therapeutics is building a pipeline of innovative drugs with a focus on cancer, immunology and inflammation. Our Co-Founder and Chief Scientific Officer, Ali Tavassoli, explains more. Simon Kerry and I co-founded Curve in 2019 with a vision to transform the lives of […]
JP Morgan 43rd Annual Healthcare Conference 13-16 January 2025 San Francisco, US CEO Simon Kerry and Head of Business Development Cora Griffin attending
2024 has been a transformational year for Curve. We kicked off the year with a significant Series A financing, raising £40.5 million from a world class syndicate which includes our existing blue chip investors Advent Life Sciences and Epidarex Capital, alongside new investment from Pfizer Ventures, Columbus Venture Partners and British Patient Capital. The financing […]
London Life Sciences Week 17-21 November 2024 London, UK CEO Simon Kerry and Head of Business Development Cora Griffin attending
BIO-Europe 2024 4-6 November 2024 Stockholm, Sweden CEO Simon Kerry and Head of Business Development Cora Griffin attending
Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. This continues Curve’s strong momentum expanding its leadership team following the recent appointments of Andre Hoekema and Cora Griffin, joining as Chair of the Board and Head of Business Development respectively.
Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development.
Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]
Biotech CEO Summit Europe 27-29 May 2024 Barcelona, Spain Simon Kerry, CEO, attending.
